617 related articles for article (PubMed ID: 31208947)
1. Validation of NEDD8-conjugating enzyme UBC12 as a new therapeutic target in lung cancer.
Li L; Kang J; Zhang W; Cai L; Wang S; Liang Y; Jiang Y; Liu X; Zhang Y; Ruan H; Chen G; Wang M; Jia L
EBioMedicine; 2019 Jul; 45():81-91. PubMed ID: 31208947
[TBL] [Abstract][Full Text] [Related]
2. Overactivated neddylation pathway as a therapeutic target in lung cancer.
Li L; Wang M; Yu G; Chen P; Li H; Wei D; Zhu J; Xie L; Jia H; Shi J; Li C; Yao W; Wang Y; Gao Q; Jeong LS; Lee HW; Yu J; Hu F; Mei J; Wang P; Chu Y; Qi H; Yang M; Dong Z; Sun Y; Hoffman RM; Jia L
J Natl Cancer Inst; 2014 Jun; 106(6):dju083. PubMed ID: 24853380
[TBL] [Abstract][Full Text] [Related]
3. Suppression of glioblastoma by targeting the overactivated protein neddylation pathway.
Hua W; Li C; Yang Z; Li L; Jiang Y; Yu G; Zhu W; Liu Z; Duan S; Chu Y; Yang M; Zhang Y; Mao Y; Jia L
Neuro Oncol; 2015 Oct; 17(10):1333-43. PubMed ID: 25904638
[TBL] [Abstract][Full Text] [Related]
4. A first-in-class inhibitor, MLN4924 (pevonedistat), induces cell-cycle arrest, senescence, and apoptosis in human renal cell carcinoma by suppressing UBE2M-dependent neddylation modification.
Xu B; Deng Y; Bi R; Guo H; Shu C; Shah NK; Chang J; Liu G; Du Y; Wei W; Wang C
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1083-1093. PubMed ID: 29667067
[TBL] [Abstract][Full Text] [Related]
5. MLN4924 (Pevonedistat), a protein neddylation inhibitor, suppresses proliferation and migration of human clear cell renal cell carcinoma.
Tong S; Si Y; Yu H; Zhang L; Xie P; Jiang W
Sci Rep; 2017 Jul; 7(1):5599. PubMed ID: 28717191
[TBL] [Abstract][Full Text] [Related]
6. Targeting DCN1-UBC12 Protein-Protein Interaction for Regulation of Neddylation Pathway.
Zhou H; Lu J; Yang CY; Sun Y; Wang S
Adv Exp Med Biol; 2020; 1217():349-362. PubMed ID: 31898237
[TBL] [Abstract][Full Text] [Related]
7. The Nedd8-activating enzyme inhibitor MLN4924 (TAK-924/Pevonedistat) induces apoptosis via c-Myc-Noxa axis in head and neck squamous cell carcinoma.
Zhang W; Liang Y; Li L; Wang X; Yan Z; Dong C; Zeng MS; Zhong Q; Liu XK; Yu J; Sun S; Liu X; Kang J; Zhao H; Jeong LS; Zhang Y; Jia L
Cell Prolif; 2019 Mar; 52(2):e12536. PubMed ID: 30341788
[TBL] [Abstract][Full Text] [Related]
8. Targeting protein neddylation with an NEDD8-activating enzyme inhibitor MLN4924 induced apoptosis or senescence in human lymphoma cells.
Wang Y; Luo Z; Pan Y; Wang W; Zhou X; Jeong LS; Chu Y; Liu J; Jia L
Cancer Biol Ther; 2015; 16(3):420-9. PubMed ID: 25782162
[TBL] [Abstract][Full Text] [Related]
9. Effective targeting of the ubiquitin-like modifier NEDD8 for lung adenocarcinoma treatment.
Jiang Y; Cheng W; Li L; Zhou L; Liang Y; Zhang W; Chen W; Wang S; Zhao H; Chen G; Zhou W; Ji G; Zhang Y; Hoffman RM; Wang M; Jia L
Cell Biol Toxicol; 2020 Aug; 36(4):349-364. PubMed ID: 31907687
[TBL] [Abstract][Full Text] [Related]
10. MLN4924 inhibits cell proliferation by targeting the activated neddylation pathway in endometrial carcinoma.
Liu H; Bei Q; Luo X
J Int Med Res; 2021 Jun; 49(6):3000605211018592. PubMed ID: 34082605
[TBL] [Abstract][Full Text] [Related]
11. Radiosensitization by the investigational NEDD8-activating enzyme inhibitor MLN4924 (pevonedistat) in hormone-resistant prostate cancer cells.
Wang X; Zhang W; Yan Z; Liang Y; Li L; Yu X; Feng Y; Fu S; Zhang Y; Zhao H; Yu J; Jeong LS; Guo X; Jia L
Oncotarget; 2016 Jun; 7(25):38380-38391. PubMed ID: 27224919
[TBL] [Abstract][Full Text] [Related]
12. Neddylation inhibitor MLN4924 suppresses growth and migration of human gastric cancer cells.
Lan H; Tang Z; Jin H; Sun Y
Sci Rep; 2016 Apr; 6():24218. PubMed ID: 27063292
[TBL] [Abstract][Full Text] [Related]
13. UBC12-mediated SREBP-1 neddylation worsens metastatic tumor prognosis.
Heo MJ; Kang SH; Kim YS; Lee JM; Yu J; Kim HR; Lim H; Kim KM; Jung J; Jeong LS; Moon A; Kim SG
Int J Cancer; 2020 Nov; 147(9):2550-2563. PubMed ID: 32449166
[TBL] [Abstract][Full Text] [Related]
14. Neddylation pathway is up-regulated in human intrahepatic cholangiocarcinoma and serves as a potential therapeutic target.
Gao Q; Yu GY; Shi JY; Li LH; Zhang WJ; Wang ZC; Yang LX; Duan M; Zhao H; Wang XY; Zhou J; Qiu SJ; Jeong LS; Jia LJ; Fan J
Oncotarget; 2014 Sep; 5(17):7820-32. PubMed ID: 25229838
[TBL] [Abstract][Full Text] [Related]
15. Targeting Neddylation pathways to inactivate cullin-RING ligases for anticancer therapy.
Zhao Y; Morgan MA; Sun Y
Antioxid Redox Signal; 2014 Dec; 21(17):2383-400. PubMed ID: 24410571
[TBL] [Abstract][Full Text] [Related]
16. Biochemical and cellular effects of inhibiting Nedd8 conjugation.
Leck YC; Choo YY; Tan CY; Smith PG; Hagen T
Biochem Biophys Res Commun; 2010 Jul; 398(3):588-93. PubMed ID: 20603103
[TBL] [Abstract][Full Text] [Related]
17. SENP8 limits aberrant neddylation of NEDD8 pathway components to promote cullin-RING ubiquitin ligase function.
Coleman KE; Békés M; Chapman JR; Crist SB; Jones MJ; Ueberheide BM; Huang TT
Elife; 2017 May; 6():. PubMed ID: 28475037
[TBL] [Abstract][Full Text] [Related]
18. Targeting Protein Neddylation for Cancer Therapy.
Zhou L; Jia L
Adv Exp Med Biol; 2020; 1217():297-315. PubMed ID: 31898235
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of the Cullin (CUL)-RING E3 ligase by the NEDD8-activating enzyme inhibitor MLN4924 triggers protective autophagy in cancer cells.
Luo Z; Pan Y; Jeong LS; Liu J; Jia L
Autophagy; 2012 Nov; 8(11):1677-9. PubMed ID: 22874562
[TBL] [Abstract][Full Text] [Related]
20. Arctigenin impairs UBC12 enzyme activity and cullin neddylation to attenuate cancer cells.
Chen YF; Liu RZ; Ying WW; Yang YN; Xiang SF; Shao XJ; Cao J; Zhang YQ; Yang B; He QJ; Ying MD
Acta Pharmacol Sin; 2023 Mar; 44(3):661-669. PubMed ID: 36138144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
